The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1126
March 18, 2002
View Complete Issue         Table of Contents 2019 
Ertapenem (Invanz) - A New Parenteral Carbapenem
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ertapenem (Invanz) - A New Parenteral Carbapenem
March 18, 2002 (Issue: 1126)
Ertapenem (er ta pen' em; Invanz - Merck), a carbapenem antibacterial with a narrower spectrum of activity than imipenem (Primaxin) or meropenem (Merrem), has been approved by the FDA for once-daily IV treatment of complicated intra-abdominal,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ertapenem (Invanz) - A New Parenteral Carbapenem
Article code: 1126a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.